{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:06:30Z","timestamp":1790265990963,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.peptides.2026.171519","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:01:17Z","timestamp":1790146877000},"page":"171519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists"],"prefix":"10.1016","volume":"201","author":[{"given":"Jianmeng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoli","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2026.171519_bib1","doi-asserted-by":"crossref","unstructured":"Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10513):1873-1922. https:\/\/doi.org\/10.1016\/s0140-6736(25)01637-x.","DOI":"10.1016\/S0140-6736(25)01637-X"},{"key":"10.1016\/j.peptides.2026.171519_bib2","doi-asserted-by":"crossref","unstructured":"2025, Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10513):1811-1872. https:\/\/doi.org\/10.1016\/s0140-6736(25)01917-8.","DOI":"10.1016\/S0140-6736(25)01917-8"},{"key":"10.1016\/j.peptides.2026.171519_bib3","series-title":"Global Burden of Disease Study 2023 (GBD 2023) Results","author":"Institute for Health M, Evaluation","year":"2023"},{"issue":"9","key":"10.1016\/j.peptides.2026.171519_bib4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jacc.2025.12.027","article-title":"Cardiovascular statistics in the United States, 2026","volume":"87","author":"Wadhera","year":"2026","journal-title":"JACC Stats. J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.peptides.2026.171519_bib5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurjpc\/zwae171","article-title":"Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review","volume":"31","author":"Tuccinardi","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11883-025-01331-w","article-title":"Novel Strategies to Conquer Residual Adiposity Risk in Cardiovascular Disease","volume":"27","author":"Philip","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"issue":"11","key":"10.1016\/j.peptides.2026.171519_bib7","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.peptides.2026.171519_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/dom.14500","article-title":"Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection","volume":"23","author":"Andreasen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11883-025-01319-6","article-title":"The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes","volume":"27","author":"Sheth","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"issue":"8","key":"10.1016\/j.peptides.2026.171519_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1113\/jphysiol.1902.sp000920","article-title":"The mechanism of pancreatic secretion","volume":"28","author":"Bayliss","year":"1902","journal-title":"J. Physiol."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.peptides.2026.171519_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell. Metab."},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s44446-025-00038-y","article-title":"GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity","volume":"33","author":"Alharbi","year":"2025","journal-title":"Saudi Pharm. J."},{"issue":"4","key":"10.1016\/j.peptides.2026.171519_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.peptides.2026.171519_bib16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.peptides.2026.171519_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.peptides.2026.171519_bib19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10157","key":"10.1016\/j.peptides.2026.171519_bib20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"10.1016\/j.peptides.2026.171519_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.peptides.2026.171519_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.peptides.2026.171519_bib23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.peptides.2026.171519_bib24","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.peptides.2026.171519_bib25","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.peptides.2026.171519_bib26","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.peptides.2026.171519_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","volume":"12","author":"Nauck","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"23","key":"10.1016\/j.peptides.2026.171519_bib28","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2026.171519_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.2792","article-title":"Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial","volume":"45","author":"Colhoun","year":"2024","journal-title":"Eur. Heart J."},{"issue":"10516","key":"10.1016\/j.peptides.2026.171519_bib30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.acvd.2025.10.206","article-title":"Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: A secondary analysis of the SELECT trial","volume":"119","author":"Shiele","year":"2026","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"8","key":"10.1016\/j.peptides.2026.171519_bib32","first-page":"493","article-title":"A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes","volume":"20","author":"Carney","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"issue":"17","key":"10.1016\/j.peptides.2026.171519_bib33","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.peptides.2026.171519_bib34","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1111\/dom.70054","article-title":"Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study","volume":"27","author":"Tang","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41591-024-03355-2","article-title":"Proteomic changes upon treatment with semaglutide in individuals with obesity","volume":"31","author":"Maretty","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib36","article-title":"Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-Analysis","volume":"18","author":"Tom-Ayegunle","year":"2026","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial","volume":"331","author":"Aronne","year":"2024","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.peptides.2026.171519_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/JME-12-0166","article-title":"Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways","volume":"50","author":"Erdogdu","year":"2013","journal-title":"J. Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.peptides.2026.171519_bib39","doi-asserted-by":"crossref","first-page":"H610","DOI":"10.1152\/ajpheart.00996.2025","article-title":"GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-\u03b21-40 in diabetes","volume":"330","author":"Ikonomidis","year":"2026","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"9","key":"10.1016\/j.peptides.2026.171519_bib40","article-title":"Mechanistic Insights Into the Cardioprotective Effects of Modern Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review","volume":"17","author":"Ratnala","year":"2025","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.peptides.2026.171519_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00592-025-02606-z","article-title":"GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes","volume":"63","author":"Gitto","year":"2026","journal-title":"Acta Diabetol."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/FJC.0000000000000087","article-title":"GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A","volume":"64","author":"Dai","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.peptides.2026.171519_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","article-title":"Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice","volume":"261","author":"Jojima","year":"2017","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib44","first-page":"3573","article-title":"Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway","volume":"17","author":"Wan","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.peptides.2026.171519_bib45","doi-asserted-by":"crossref","first-page":"H295","DOI":"10.1152\/ajpheart.00990.2012","article-title":"Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes","volume":"305","author":"Monji","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.peptides.2026.171519_bib46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1535370214522177","article-title":"Exenatide protects against hypoxia\/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells","volume":"239","author":"Chang","year":"2014","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"23","key":"10.1016\/j.peptides.2026.171519_bib47","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.4103\/0366-6999.170259","article-title":"Exenatide Reduces Tumor Necrosis Factor-\u03b1-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction","volume":"128","author":"Cao","year":"2015","journal-title":"Chin. Med. J. (Engl. )"},{"issue":"10","key":"10.1016\/j.peptides.2026.171519_bib48","article-title":"Liraglutide Enhances Cell Viability and Reduces Oxidative Stress in Hyperglycemic H9c2 Cardiomyocytes","volume":"61","author":"Durmus","year":"2025","journal-title":"Med. (Kaunas. )"},{"issue":"2","key":"10.1016\/j.peptides.2026.171519_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12012-026-10095-x","article-title":"Liraglutide Modulates Zinc Release and Improves Mitochondrial Function in Insulin-Resistant Senescent Cardiomyocytes","volume":"26","author":"Hosseinpourshirazi","year":"2026","journal-title":"Cardiovasc. Toxicol."},{"issue":"8","key":"10.1016\/j.peptides.2026.171519_bib50","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41401-024-01265-0","article-title":"Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway","volume":"45","author":"Ni","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12933-025-02806-5","article-title":"Tirzepatide, a dual GIP\/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide","volume":"24","author":"Heged\u0171s","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.peptides.2026.171519_bib52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction","volume":"84","author":"Schou","year":"2024","journal-title":"STEP-HFpEF Program. J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.peptides.2026.171519_bib53","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program","volume":"84","author":"Verma","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.peptides.2026.171519_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"issue":"10","key":"10.1016\/j.peptides.2026.171519_bib55","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","article-title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","volume":"34","author":"Wong","year":"2022","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell. Metab."},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib57","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s11010-023-04784-2","article-title":"Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression","volume":"479","author":"Pan","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.peptides.2026.171519_bib58","article-title":"Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss","author":"Elbatreek","year":"2025","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.peptides.2026.171519_bib59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","article-title":"Epicardial adipose tissue in contemporary cardiology","volume":"19","author":"Iacobellis","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.peptides.2026.171519_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pcad.2023.04.006","article-title":"Epicardial fat links obesity to cardiovascular diseases","volume":"78","author":"Iacobellis","year":"2023","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-024-02342-8","article-title":"Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia\/reperfusion through modulating macrophages polarization","volume":"23","author":"Zhao","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"10.1016\/j.peptides.2026.171519_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2024.08.019","article-title":"Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control","volume":"35","author":"Iacobellis","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib63","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2337\/db12-1025","article-title":"Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP\/PKA\/Rho-dependent mechanism","volume":"62","author":"Wang","year":"2013","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.peptides.2026.171519_bib65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijcard.2018.12.005","article-title":"Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction","volume":"283","author":"Suhrs","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108188","article-title":"A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study)","volume":"36","author":"Loganathan","year":"2022","journal-title":"J. Diabetes Complicat."},{"issue":"7","key":"10.1016\/j.peptides.2026.171519_bib67","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"issue":"10454","key":"10.1016\/j.peptides.2026.171519_bib68","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.peptides.2026.171519_bib69","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"10.1016\/j.peptides.2026.171519_bib70","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib71","first-page":"846","article-title":"Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2026.171519_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-026-10330-z","article-title":"Genetic predictors of GLP1 receptor agonist weight loss and side effects","author":"Su","year":"2026","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.peptides.2026.171519_bib73","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10437","key":"10.1016\/j.peptides.2026.171519_bib74","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib75","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.peptides.2026.171519_bib76","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"24","key":"10.1016\/j.peptides.2026.171519_bib77","article-title":"Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database","volume":"14","author":"Osei","year":"2024","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.peptides.2026.171519_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.peptides.2026.171519_bib79","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 receptor agonist use and risk of suicide death","volume":"184","author":"Ueda","year":"2024","journal-title":"JAMA Intern. Med."},{"issue":"10531","key":"10.1016\/j.peptides.2026.171519_bib80","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2026.171519_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109252","article-title":"GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1\u03b2-induced metabolic disturbance and mitochondrial dysfunction","volume":"332","author":"Zhang","year":"2020","journal-title":"Chem. Biol. Interact."},{"issue":"9","key":"10.1016\/j.peptides.2026.171519_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094900","article-title":"Peptides ARe Cardioprotective Drugs of the Future: the Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists","volume":"25","author":"Boshchenko","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.peptides.2026.171519_bib83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-024-02203-4","article-title":"Evidence that tirzepatide protects against diabetes-related cardiac damages","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:28:00Z","timestamp":1790263680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978126000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":83,"alternative-id":["S0196978126000562"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171519","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"171519"}}